Sanofi secured approvals from China’s National Medical Products Administration for its two rare‑disease therapies, Myqorzo (aficamten) and Redemplo (plozasiran), granting the company commercial rights in the Greater China market.
Myqorzo is a selective cardiac myosin inhibitor that treats obstructive hypertrophic cardiomyopathy, while Redemplo is an siRNA medicine designed to lower triglyceride levels in patients with familial chylomicronemia syndrome. Both drugs address unmet medical needs in rare‑disease populations.
The approvals expand Sanofi’s footprint in one of the world’s largest pharmaceutical markets and add new revenue streams to its General Medicines segment. They also reinforce the company’s broader strategy to diversify beyond its core specialty and vaccine businesses and to focus on high‑growth, high‑margin therapeutics.
China’s NMPA has accelerated approvals for innovative rare‑disease drugs, and this move positions Sanofi to capture a growing market for treatments that are currently underserved. The approvals follow Myqorzo’s U.S. FDA clearance in December 2025 and the 2025 acquisition of Redemplo rights in Greater China.
Management highlighted the strategic importance of entering the Chinese rare‑disease market, noting that the approvals support Sanofi’s commitment to expanding access to innovative therapies and to strengthening its biopharma portfolio.
revised_sentiment_rating
importance
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.